{"id":"first-line-antiretroviral-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Lipodystrophy"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Lactic acidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"First-line antiretroviral regimens usually consist of two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) plus either a non-nucleoside reverse transcriptase inhibitor (NNRTI), protease inhibitor (PI), or integrase strand transfer inhibitor (INSTI). These agents work synergistically to block different stages of the HIV replication cycle, preventing viral spread and allowing CD4+ T-cell recovery. The specific combination depends on patient factors, resistance patterns, and tolerability.","oneSentence":"First-line antiretroviral therapy typically combines multiple HIV drugs that inhibit viral reverse transcriptase, protease, or integrase to suppress HIV replication and restore immune function.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:30:37.090Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection, treatment-naïve patients"},{"name":"AIDS prevention and viral load suppression"}]},"trialDetails":[{"nctId":"NCT05165810","phase":"NA","title":"Evaluation of Multiple Interventions to Improve HIV Treatment Outcomes Among People Who Inject Drugs in India","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2023-03-09","conditions":"HIV Infections","enrollment":800},{"nctId":"NCT00931463","phase":"PHASE4","title":"A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2009-09","conditions":"HIV Infections","enrollment":558},{"nctId":"NCT05994742","phase":"PHASE3","title":"An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Queen Mary University of London","startDate":"2024-07-15","conditions":"Severe Acute Malnutrition, HIV, Comorbidities and Coexisting Conditions","enrollment":674},{"nctId":"NCT05917509","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2023-07-06","conditions":"HIV Infections","enrollment":171},{"nctId":"NCT02591420","phase":"PHASE1","title":"Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-04","conditions":"HIV Infections","enrollment":24},{"nctId":"NCT05841797","phase":"NA","title":"Evaluation of Problem Management Plus in Pregnant Women With HIV in Kenya","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2023-06-05","conditions":"Human Immunodeficiency Virus","enrollment":120},{"nctId":"NCT05979311","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2024-02-09","conditions":"HIV, HIV Infections","enrollment":473},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT03092505","phase":"","title":"Herpesviruses Reactivation In Hiv-Infected Women Initiating ART (HERA)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-06-15","conditions":"Herpes Virus-Related Illnesses","enrollment":190},{"nctId":"NCT04518228","phase":"","title":"Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-01","conditions":"HIV Infections, Tuberculosis","enrollment":205},{"nctId":"NCT03385473","phase":"NA","title":"Individualized Antiretroviral Therapy","status":"COMPLETED","sponsor":"Hospital Italiano de Buenos Aires","startDate":"2017-10-05","conditions":"Pharmacogenetics, HIV, Drug Monitoring","enrollment":190},{"nctId":"NCT03800407","phase":"","title":"Contributing Factors for Poor HIV Treatment Response in Children With TB/HIV Coinfection","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-01-28","conditions":"Tuberculosis, Human Immunodeficiency Virus, Coinfection","enrollment":213},{"nctId":"NCT02259127","phase":"PHASE2, PHASE3","title":"ODYSSEY (PENTA 20)","status":"COMPLETED","sponsor":"PENTA Foundation","startDate":"2016-09-20","conditions":"HIV Infection","enrollment":792},{"nctId":"NCT04026867","phase":"NA","title":"The DETECT HCV Linkage to Care Trial","status":"COMPLETED","sponsor":"Denver Health and Hospital Authority","startDate":"2019-11-20","conditions":"Hepatitis C","enrollment":309},{"nctId":"NCT05044962","phase":"NA","title":"Kuwa Free! - Live Free!","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-11-26","conditions":"HIV Infections, Contraception, Drug-drug Interaction","enrollment":700},{"nctId":"NCT05924438","phase":"PHASE3","title":"A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Professor Francois Venter","startDate":"2023-11-08","conditions":"HIV-1-infection","enrollment":600},{"nctId":"NCT05222945","phase":"NA","title":"A Study to Determine the Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Patients Treated by a First Line Treatment Containing bictégravir, Emtricitabine and ténofovir alafénamide","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-04-01","conditions":"HIV-1-infection","enrollment":34},{"nctId":"NCT04019873","phase":"","title":"'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2019-11-18","conditions":"HIV Infections","enrollment":774},{"nctId":"NCT03800381","phase":"","title":"Adequacy of the New Pediatric Isoniazid/Rifampin/Pyrazinamide (HRZ) Tablet","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-01-28","conditions":"Tuberculosis, Human Immunodeficiency Virus, Coinfection","enrollment":92},{"nctId":"NCT03991013","phase":"PHASE2","title":"Tenofovir-lamivudine-dolutegravir Combination as Second-line ART: a Randomised Controlled Trial","status":"COMPLETED","sponsor":"University of Cape Town","startDate":"2019-08-08","conditions":"HIV Infections","enrollment":192},{"nctId":"NCT05546242","phase":"PHASE3","title":"Improving HIV-1 Control in Africa with Long Acting Antiretrovirals","status":"ACTIVE_NOT_RECRUITING","sponsor":"MRC/UVRI and LSHTM Uganda Research Unit","startDate":"2022-12-08","conditions":"HIV-1-infection","enrollment":540},{"nctId":"NCT04133012","phase":"NA","title":"Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Patients Treated by a First Line Treatment Containing Dolutegravir and Associated Nucleoside / Nucleotide Reverse Transcriptase Inhibitors Backbone","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2020-02-10","conditions":"HIV-1 Infection","enrollment":20},{"nctId":"NCT06518213","phase":"","title":"Efficacy and Safety of First-line ART With BIC/FTC/TAF Introduced at the First Clinical Visit","status":"COMPLETED","sponsor":"University Hospital for Infectious Diseases, Croatia","startDate":"2019-05-01","conditions":"HIV Infections","enrollment":112},{"nctId":"NCT04253119","phase":"","title":"ART First-line Treatment Durability in Russia","status":"COMPLETED","sponsor":"MSD Pharmaceuticals LLC","startDate":"2019-11-26","conditions":"HIV-1-infection","enrollment":536},{"nctId":"NCT04653194","phase":"PHASE3","title":"Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'","status":"COMPLETED","sponsor":"Chelsea and Westminster NHS Foundation Trust","startDate":"2020-09-30","conditions":"Human Immunodeficiency Virus","enrollment":36},{"nctId":"NCT04022967","phase":"PHASE3","title":"ANRS 12372 MODERATO Study","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2020-09-21","conditions":"HIV-1-infection","enrollment":480},{"nctId":"NCT04050449","phase":"","title":"Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of TLD","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2019-10-28","conditions":"HIV-1-infection","enrollment":1339},{"nctId":"NCT04433780","phase":"PHASE3","title":"DORA: A Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV","status":"COMPLETED","sponsor":"Professor Francois Venter","startDate":"2021-01-04","conditions":"HIV-1-infection","enrollment":133},{"nctId":"NCT02787499","phase":"NA","title":"Resistance Testing to Improve Management of Virologic Failure in Sub-Saharan Africa","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2016-12-08","conditions":"HIV, AIDS","enrollment":840},{"nctId":"NCT02227238","phase":"PHASE3","title":"Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-12-11","conditions":"HIV Infections","enrollment":627},{"nctId":"NCT03122262","phase":"PHASE3","title":"ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy","status":"COMPLETED","sponsor":"Professor Francois Venter","startDate":"2017-01-16","conditions":"HIV-1 Infection","enrollment":1110},{"nctId":"NCT04429152","phase":"PHASE3","title":"ADORE: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With NNRTI Resistance","status":"UNKNOWN","sponsor":"Professor Francois Venter","startDate":"2021-02-09","conditions":"HIV-1-infection","enrollment":25},{"nctId":"NCT03357588","phase":"NA","title":"The Intensified Treatment Monitoring Strategy to Prevent Accumulation of Drug Resistance (ITREMA) Trial","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2015-06-29","conditions":"HIV/AIDS","enrollment":501},{"nctId":"NCT00102960","phase":"PHASE3","title":"Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-07","conditions":"HIV Infections","enrollment":377},{"nctId":"NCT02369965","phase":"PHASE3","title":"Test Albuvirtide in Experienced Patients","status":"COMPLETED","sponsor":"Frontier Biotechnologies Inc.","startDate":"2014-02-19","conditions":"HIV Infections, AIDS","enrollment":418},{"nctId":"NCT01709084","phase":"PHASE3","title":"A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2013-10-02","conditions":"Human Immunodeficiency Virus-type 1 Infection","enrollment":426},{"nctId":"NCT01225406","phase":"","title":"Third Line Highly Active Antiretroviral Therapy (HAART) in HIV-infected Children","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2010-08","conditions":"This Study is Designed to Collect Treatment Data of Thai Children on Third Line ARV Therapy","enrollment":56},{"nctId":"NCT04388514","phase":"NA","title":"Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure","status":"UNKNOWN","sponsor":"Azienda Sanitaria-Universitaria Integrata di Udine","startDate":"2020-04-08","conditions":"SARS-CoV-2 Respiratory Failure","enrollment":90},{"nctId":"NCT03858478","phase":"PHASE4","title":"Initiation of First-line Antiretroviral Treatment With TENOFOVIR ALAFENAMIDE - EMTRICITABINE - BICTEGRAVIR at the First Clinical Contact in France: Trial IMEA 055 - FAST","status":"UNKNOWN","sponsor":"Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba","startDate":"2019-11-18","conditions":"HIV Seropositivity","enrollment":110},{"nctId":"NCT00434070","phase":"","title":"Relationship of Viral Resistance Development to CD4 Monitoring Alone or With Viral Load Monitoring","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-02-07","conditions":"Acquired Immunodeficiency Syndrome, Resistance","enrollment":1012},{"nctId":"NCT02150993","phase":"PHASE2, PHASE3","title":"First-Line Treatment for HIV-2","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2016-01-26","conditions":"HIV-2 Infection","enrollment":210},{"nctId":"NCT02946762","phase":"NA","title":"TasP in Correctional Facilities","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2016-02-01","conditions":"HIV, Tuberculosis","enrollment":419},{"nctId":"NCT03280940","phase":"","title":"Impact of Different Integrase Inhibitor Based Regimen on Immune Activation Among HIV naïve Patient (INTATTI)","status":"COMPLETED","sponsor":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","startDate":"2017-09-01","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT03789448","phase":"NA","title":"Early Access to ART for All in Swaziland: Effects on Economic Outcomes","status":"COMPLETED","sponsor":"Till Bärnighausen","startDate":"2014-09-01","conditions":"HIV/AIDS","enrollment":3019},{"nctId":"NCT01317498","phase":"NA","title":"The VMVN Study: Virological Monitoring in Viet Nam","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2011-04","conditions":"HIV Infection, AIDS","enrollment":650},{"nctId":"NCT00428116","phase":"NA","title":"Optimizing Pediatric HIV-1 Treatment, Nairobi, Kenya","status":"TERMINATED","sponsor":"University of Washington","startDate":"2007-09","conditions":"HIV Infections","enrollment":140},{"nctId":"NCT02381275","phase":"","title":"The Lighthouse Tenofovir Cohort Study","status":"UNKNOWN","sponsor":"Lighthouse Trust","startDate":"2014-08-14","conditions":"Chronic Renal Disease","enrollment":1500},{"nctId":"NCT03478540","phase":"","title":"Gut Microbiota and Immune Recovery","status":"UNKNOWN","sponsor":"Shanghai Public Health Clinical Center","startDate":"2017-12-01","conditions":"HIV-1-infection","enrollment":80},{"nctId":"NCT02624453","phase":"NA","title":"Pre-Antiretroviral Therapy (ART) Cryptococcal Antigen Screening in AIDS","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2015-07","conditions":"Cryptococcal Meningitis","enrollment":186},{"nctId":"NCT01637558","phase":"PHASE4","title":"Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)","status":"COMPLETED","sponsor":"University of Cape Town","startDate":"2012-11","conditions":"Tuberculosis, HIV","enrollment":200},{"nctId":"NCT00928187","phase":"PHASE3","title":"Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2009-11","conditions":"HIV, HIV Infections","enrollment":454},{"nctId":"NCT00830856","phase":"NA","title":"Early Versus Delayed Antiretroviral Therapy (ART) in the Treatment of Cryptococcal Meningitis in Africa","status":"COMPLETED","sponsor":"University of Zimbabwe","startDate":"2006-10","conditions":"Cryptococcal Meningitis, HIV Infections","enrollment":54},{"nctId":"NCT01348308","phase":"PHASE3","title":"Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2011-09","conditions":"HIV-1 Infection, AIDS","enrollment":407},{"nctId":"NCT02126696","phase":"","title":"Comorbidities and Virologic Outcome Among Patients on Anti-retroviral Therapy in Rural Lesotho","status":"COMPLETED","sponsor":"Swiss Tropical & Public Health Institute","startDate":"2014-05","conditions":"HIV, Metabolic Syndrome, Depression","enrollment":1754},{"nctId":"NCT00753324","phase":"PHASE4","title":"Routine Use of Antiretroviral Therapy to Prevent Mother-to-Child HIV Transmission in the Kafue District of Zambia","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2009-05","conditions":"HIV Infections","enrollment":284},{"nctId":"NCT01192035","phase":"PHASE4","title":"PI or NNRTI as First-line Treatment of HIV in West Africa - the PIONA Trial","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2011-05","conditions":"HIV-1","enrollment":400},{"nctId":"NCT00050089","phase":"NA","title":"CSP #512 - Options in Management With Anti-Retrovirals","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2001-01","conditions":"AIDS, HIV Infections","enrollment":368},{"nctId":"NCT01844297","phase":"NA","title":"Efficacy and Safety of Tenofovir Plus Lamivudine Plus Efavirenz Regimen as First-line Antiretroviral Therapy","status":"UNKNOWN","sponsor":"Peking Union Medical College","startDate":"2013-05","conditions":"AIDS/HIV PROBLEM","enrollment":500},{"nctId":"NCT00885287","phase":"PHASE4","title":"Interactions Between Artemether-lumefantrine and Antiretrovirals in HIV-patients With Uncomplicated Malaria in Tanzania","status":"COMPLETED","sponsor":"University of Copenhagen","startDate":"2009-07","conditions":"Malaria, Falciparum, HIV Infections","enrollment":830},{"nctId":"NCT01038999","phase":"","title":"Accelerated Aging, HIV Infection, Antiretroviral Therapies","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2009-04","conditions":"HIV Infection, Aging Accelerated, Antiretroviral Therapies","enrollment":200},{"nctId":"NCT00389402","phase":"PHASE4","title":"BASIC: Boosted Atazanavir or Saquinavir Induced Lipid Changes","status":"COMPLETED","sponsor":"International Antiviral Therapy Evaluation Center","startDate":"2006-07","conditions":"HIV Infections","enrollment":120},{"nctId":"NCT01049685","phase":"PHASE4","title":"Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy","status":"UNKNOWN","sponsor":"UPECLIN HC FM Botucatu Unesp","startDate":"2006-08","conditions":"HIV Infections","enrollment":36},{"nctId":"NCT00466258","phase":"PHASE4","title":"LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2006-10","conditions":"HIV Infections, Diffuse Large B Cell Lymphoma","enrollment":50},{"nctId":"NCT00872417","phase":"PHASE4","title":"Study on the Antiviral Therapy and Immune Reconstitution of Chinese HIV/AIDS Patients","status":"UNKNOWN","sponsor":"Peking Union Medical College","startDate":"2009-03","conditions":"Acquired Immune Deficiency Syndrome, HIV Infections","enrollment":750}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":691,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sustiva","Kaletra"],"phase":"marketed","status":"active","brandName":"First-line Antiretroviral Therapy","genericName":"First-line Antiretroviral Therapy","companyName":"UPECLIN HC FM Botucatu Unesp","companyId":"upeclin-hc-fm-botucatu-unesp","modality":"Small molecule","firstApprovalDate":"","aiSummary":"First-line antiretroviral therapy typically combines multiple HIV drugs that inhibit viral reverse transcriptase, protease, or integrase to suppress HIV replication and restore immune function. Used for HIV-1 infection, treatment-naïve patients, AIDS prevention and viral load suppression.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}